CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study Dapagliflozin for treating chronic heart failure with reduced ejection fraction The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors Criteria for Iron Deficiency in Patients With Heart Failure The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|<<... 9 10 11 12 13 14 15 16 >>|

Clinical TrialDecember 8, 2020 Vol 142, Issue 23

JOURNAL：Circulation. Article Link

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial

F Cosentino , CP Cannon , DZI Cherney et al. Keywords: ertugliflozin;T2DM; ASCVD, HF

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top